Advances in Ovarian Cancer Treatment Beyond PARP Inhibitors

Area of Science:

• Gynecologic Oncology
• Molecular Biology
• Translational Medicine

Background:

• Ovarian cancer is the leading cause of gynecological cancer mortality, often diagnosed late with no effective screening.
• The disease's heterogeneity necessitates diverse therapeutic strategies.
• Advances in understanding molecular pathways have led to targeted therapies.

Purpose of the Study:

• To review molecular, preclinical, and clinical evidence for targeting growth-dependent pathways in ovarian cancer.
• To assess current targeted treatments, focusing on agents beyond Poly(ADP-ribose) polymerase (PARP) inhibitors.
• To highlight novel biomarkers like microRNAs for diagnosis and therapy.

Main Methods:

• Literature review of molecular, preclinical, and clinical studies.
• Analysis of targeted agents including PARP inhibitors, anti-VEGF-A antibodies, and PI3K/AKT/mTOR pathway inhibitors.
• Evaluation of emerging biomarkers such as microRNAs.

Main Results:

• Poly(ADP-ribose) polymerase (PARP) inhibitors and anti-VEGF-A antibodies are established targeted therapies.
• Tyrosine kinase inhibitors targeting angiogenic pathways and treatments for the PI3K/AKT/mTOR pathway are under investigation.
• MicroRNAs show promise as diagnostic and therapeutic biomarkers.

Conclusions:

• Targeted therapies, particularly those beyond PARP inhibitors, offer significant potential for improving ovarian cancer treatment.
• Further research into molecular pathways and novel biomarkers is crucial for advancing ovarian cancer care.
• Personalized treatment strategies based on molecular subsets are key to overcoming treatment resistance.